arrow
A

Adrien Costantini

pathology
H指数:12
被引数:651

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NSCLC brain metastases exhibit reduced HLA-I antigen presentation machinery and immune evasion independent of IFNγ signaling defects

NSCLC脑转移瘤表现出HLA-I抗原呈递机器减少和免疫逃逸,且与IFNγ信号缺陷无关

2026-05-280
OA
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs)

可溶性PD-L1(sPD-L1)作为接受一线免疫检查点抑制剂(ICIs)治疗的晚期非小细胞肺癌(NSCLC)患者中持久应答和生存的生物标志物

2025-08-260
OAAI
Corrigendum to “AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium”. [Lung Cancer 205 (2025) 108610]

勘误:“OPTIMA联盟对肺癌管理临床实践指南的AGREE-II评估”[Lung Cancer 205 (2025) 108610]。

2025-07-080
OA
AGREE-II appraisal of lung cancer management clinical practice guidelines by the OPTIMA consortium

OPTIMA联盟对肺癌管理临床实践指南的AGREE-II评估

2025-06-030
OA
Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer

HGF/c-MET通路在晚期非小细胞肺癌对免疫检查点抑制剂耐药中的作用

2025-01-030
OA